Supplementary Material for: Concentric reversible visual field loss, nyctalopia and dyschromatopsia with ezetimibe therapy

This is a case of ezetimibe induced concentric field loss, dyschromatopsia and nyctalopia in a patient with no prior history of retinal dystrophy or drug hypersensitivity. A 55-year-old Caucasian woman presents with a one-year history of increasing concentric visual field loss, nyctalopia, photophobia and colour vision impairment. These symptoms correlated with the commencement of ezetimibe therapy 10 mg daily for hypercholesterolaemia. She demonstrated repeatable bilateral visual field constriction on 30-2 Humphrey visual filed testing and colour vision impairment on Ishihara plates (OD:1/17, OS:1/17). Biochemical and radiological screening for carcinoma associated retinopathy was unremarkable. A working diagnosis of drug induced rod-cone dysfunction was made. Her visual symptoms and field changes completely resolved three months after cessation of ezetimibe therapy. This case suggests that ezetimibe is a potential cause of rod-cone dysfunction and should be considered as a differential in patients with new unexplained visual symptoms.